MedTrace Logo

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

NCT02512926 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-10-15

No results posted yet for this study

Summary

This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia.

Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.

Conditions

  • Relapsed Solid Tumors
  • Refractory Solid Tumors
  • Relapsed Leukemia
  • Refractory Leukemia

Interventions

DRUG

Carfilzomib

Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias

DRUG

Cyclophosphamide

DRUG

Etoposide

Sponsors & Collaborators

  • Pediatric Oncology Experimental Therapeutics Investigators' Consortium

    collaborator UNKNOWN

  • Amgen

    collaborator INDUSTRY

  • Stanford University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-16
Primary Completion
2021-08-28
Completion
2023-11-07

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02512926 on ClinicalTrials.gov